|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 263,90 EUR | +2,01% |
|
-4,04% | +10,60% |
| 17/04 | UCB neemt Neurona Therapeutics over | AM |
| 17/04 | Belgisch UCB neemt Neurona Therapeutics over voor maximaal 1,15 miljard dollar | RE |
Belangrijkste concurrenten
Toevoegen aan een lijst 0 geselecteerde | Omzet (Y-1) | Nettomarge (Y-1) | Ebit-marge (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | |
|---|---|---|---|---|---|---|---|
 | 9,09 mld. | 20,13% | 25,95% | 14,03% | 6,99% | -0x | |
| 14,34 mld. | 31,41% | 34,05% | 16,13% | 12,48% | -1.09x | |
| 3,95 mld. | 31,29% | 39,94% | 17,59% | 11,33% | -0.18x | |
| 15,56 mld. | 19,3% | 28,72% | 16,36% | 7,75% | 1.74x | |
| 9,89 mld. | 13,07% | 28,69% | 7,39% | 4,5% | 0.68x | |
| 1,94 mld. | -145,16% | -158,13% | -28,87% | -21,31% | 2.03x | |
| 1,29 mld. | -1% | -8,02% | -0,74% | -0,45% | -11.4x | |
| 5,14 mld. | 25,03% | 31,43% | 31,7% | 22,02% | -1.81x | |
| 3,06 mld. | 1,69% | 28,34% | 14,97% | 0,67% | 0.88x | |
| 502 mln. | -144,39% | -104,25% | - | -78,14% | -2.48x | |
| 150 mln. | 66,87% | 49,52% | 39,67% | 25,58% | 1.24x | |
| 3,22 mld. | 10,83% | 12,71% | 5,94% | 4,79% | -1.97x | |
| 638 mln. | -28,69% | -26,12% | -252,11% | -29,11% | 0.85x | |
| 389 mln. | 52,64% | 41,45% | 18,91% | - | - | |
| 1,25 mld. | 22,95% | 28,06% | 14,19% | 8,74% | 0.28x | |
| 308 mln. | 4,73% | 4,18% | 0,85% | - | -5.29x | |
| 8,83 mld. | 5,34% | 18,49% | 6,14% | 2,42% | 4.83x | |
| 357 mln. | -33,66% | -31,98% | -14,1% | -7,25% | -2.14x | |
| Gemiddelde | 4,44 mld. | -2,65% | 2,39% | -5,41% | -1,81% | -0,81x | |
| Gewogen gemiddelde per kap. | 7,54 mld. | 6,91% | 12,66% | 6,25% | 3,45% | -0,60x |
- Beurs
- Aandelen
- Koers UCB
- Sector UCB
- Financiële vergelijkingen
Kies jouw editie
Alle financiële informatie op nationaal niveau
